Denmark Glp-1 Receptor Agonist Market Size & Outlook
Denmark glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Denmark glp-1 receptor agonist market highlights
- The Denmark glp-1 receptor agonist market generated a revenue of USD 283.0 million in 2023 and is expected to reach USD 1,357.2 million by 2030.
- The Denmark market is expected to grow at a CAGR of 25.1% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 283.0 million |
| Market revenue in 2030 | USD 1,357.2 million |
| Growth rate | 25.1% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Denmark accounted for 0.8% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Denmark glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 49.47% in 2023. Horizon Databook has segmented the Denmark glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), wegovy (semaglutide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
The Denmark GLP-1 receptor agonist market is driven by factors such as well-established healthcare infrastructure, high disease burden, and growing demand for novel therapeutics to manage the disease burden.
Moreover, the country gets investments from major players due to favorable government initiatives for the biotechnology and pharmaceutical sectors. For instance, in December 2021, Novo Holdings received USD 91.7 million in funding for developing a Danish bioproduction startup focused on manufacturing peptides & proteins.
Furthermore, in July 2023, Novo Nordisk developed Ozempic to revolutionize weight loss. The company has been a developer and manufacturer of Ozepmic & Wegovy and recently expanded its application. Such initiatives are propelling the demand for effective therapeutics, further driving the overall market growth in the country.
Reasons to subscribe to Denmark glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Denmark glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Denmark glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Denmark glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Denmark GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
